Tot Biopharm International Co
Tot Biopharm International Co., a leading player in the biopharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2016, the company has rapidly established itself as a key innovator in the development of high-quality biopharmaceutical products, particularly in the fields of oncology and autoimmune diseases. With a robust portfolio that includes monoclonal antibodies and biosimilars, Tot Biopharm distinguishes itself through its commitment to advanced research and development, ensuring that its offerings meet stringent international standards. The company has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its market position as a trusted provider of biopharmaceutical solutions. Through its dedication to innovation and quality, Tot Biopharm continues to make a meaningful impact in the global healthcare landscape.
DitchCarbon Score
How does Tot Biopharm International Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tot Biopharm International Co's score of 17 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Tot Biopharm International Co's reported carbon emissions
In 2023, Tot Biopharm International Co, headquartered in China (CN), reported total carbon emissions of approximately 15,812,000 kg CO2e. This figure includes 4,957,000 kg CO2e from Scope 1 emissions and 10,855,000 kg CO2e from Scope 2 emissions. The company's emissions have shown a trend of fluctuation over the years, with a notable increase from 2022, where total emissions were about 11,431,000 kg CO2e. In 2022, Tot Biopharm's Scope 1 emissions were 4,516,000 kg CO2e, and Scope 2 emissions were 6,915,000 kg CO2e. The previous year, 2021, saw total emissions of approximately 15,014,000 kg CO2e, with Scope 1 at 4,722,000 kg CO2e and Scope 2 at 10,291,000 kg CO2e. The company’s emissions peaked in 2020 at about 14,769,000 kg CO2e, with Scope 1 emissions of 5,075,000 kg CO2e and Scope 2 emissions of 9,693,000 kg CO2e. Despite these figures, Tot Biopharm has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction strategies suggests a need for further engagement in climate action and sustainability practices within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 3,562,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,757,000 | 0,000,000 | 00,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 11,319,000 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tot Biopharm International Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
